THTX Stock Forecast 2025-2026
Distance to THTX Price Targets
THTX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Theratechnologies (THTX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on THTX and similar high-potential opportunities.
Latest THTX Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, THTX has a bullish consensus with a median price target of $3.81 (ranging from $3.81 to $3.81). Currently trading at $1.55, the median forecast implies a 146.4% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
THTX Analyst Ratings
THTX Price Target Range
Latest THTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for THTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 11, 2024 | Jones Trading | Justin Walsh | Hold | Downgrade | $0.00 |
| Jul 17, 2023 | JonesTrading | Justin Walsh | Buy | Maintains | $3.00 |
| Jul 13, 2023 | Cantor Fitzgerald | Louis Chen | Overweight | Reiterates | $9.00 |
| Nov 17, 2022 | Cantor Fitzgerald | Louis Chen | Overweight | Initiates | $9.00 |
| Jul 29, 2021 | Canaccord Genuity | Edward Nash | Hold | Downgrade | $3.00 |
| Apr 19, 2021 | Canaccord Genuity | Buy | Maintains | $8.00 | |
| Apr 15, 2020 | Canaccord Genuity | Edward Nash | Buy | Maintains | $11.00 |
| Dec 11, 2019 | Mackie Research | Buy | Upgrade | $0.00 |
Theratechnologies Inc. (THTX) Competitors
The following stocks are similar to Theratechnologies based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Theratechnologies Inc. (THTX) Financial Data
Theratechnologies Inc. has a market capitalization of $72.26M with a P/E ratio of -9.1x. The company generates $85.87M in trailing twelve-month revenue with a -9.7% profit margin.
Revenue growth is +6.6% quarter-over-quarter, while maintaining an operating margin of +3.7% and return on equity of +32.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Theratechnologies Inc. (THTX) Business Model
About Theratechnologies Inc.
Develops innovative biopharmaceutical therapies.
Theratechnologies generates revenue by developing and commercializing specialized therapies targeting unmet medical needs in endocrinology and oncology. The company focuses on niche markets, primarily through its flagship products like Egrifta SV for HIV-associated lipodystrophy and Trogarzo for multidrug-resistant HIV-1, which cater to specific patient populations.
Operating mainly in North American and European markets, Theratechnologies utilizes its expertise in peptide technology and biologics to enhance its therapeutic offerings. The company is committed to advancing specialty care for complex health issues and improving patients' quality of life, with ongoing research and development efforts that position it as a leader in biotechnological advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
103
CEO
Mr. Paul Lévesque
Country
Canada
IPO Year
N/A
Website
www.theratech.comTheratechnologies Inc. (THTX) Latest News & Analysis
Theratechnologies Inc. presented data emphasizing the limitations of BMI in assessing cardiovascular risk in people with HIV, advocating for screening of excess visceral abdominal fat for better risk identification.
New data from Theratechnologies suggests a shift in cardiovascular risk assessment for HIV patients, potentially influencing treatment protocols and market demand for their products.
Clinical results indicate that patients on ibalizumab-containing regimens achieve similar virus undetectability levels as controls, even with higher baseline HIV severity.
The results indicate ibalizumab's effectiveness in severe HIV cases, potentially boosting its market value and impacting related biotech stocks positively.
Theratechnologies Inc. (NASDAQ:THTX) will hold its Q4 2024 earnings conference call on February 26, 2024, at 8:30 AM ET with key executives participating.
Theratechnologies' Q4 earnings call indicates upcoming financial results, which can influence stock performance and investor sentiment based on company growth and outlook.
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
1 month agoTheratechnologies Inc. reported Q4 and full-year results for FY 2024, ending November 30, 2024. The company focuses on innovative biopharmaceutical therapies. Results are in USD.
Theratechnologies' Q4 and full-year results can indicate financial health and growth potential, influencing stock performance and investor sentiment in the biopharmaceutical sector.
Theratechnologies Inc. (TSX: TH, NASDAQ: THTX) will report its Q4 and full-year fiscal 2024 financial results on February 26, 2025, at 8:30 a.m. ET.
Theratechnologies' upcoming financial results and business update could impact stock performance, signaling growth potential or challenges that affect investor sentiment and decisions.
Theratechnologies has resumed distribution of EGRIFTA SV® after FDA approval, allowing the release of two manufactured batches for immediate shipment to pharmacies.
Theratechnologies' resumption of EGRIFTA SV distribution signals regulatory approval, potentially boosting revenue and market confidence, impacting stock performance positively.
Frequently Asked Questions About THTX Stock
What is Theratechnologies Inc.'s (THTX) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Theratechnologies Inc. (THTX) has a median price target of $3.81. The highest price target is $3.81 and the lowest is $3.81.
Is THTX stock a good investment in 2025?
According to current analyst ratings, THTX has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for THTX stock?
Wall Street analysts predict THTX stock could reach $3.81 in the next 12 months. This represents a 146.4% increase from the current price of $1.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Theratechnologies Inc.'s business model?
Theratechnologies generates revenue by developing and commercializing specialized therapies targeting unmet medical needs in endocrinology and oncology. The company focuses on niche markets, primarily through its flagship products like Egrifta SV for HIV-associated lipodystrophy and Trogarzo for multidrug-resistant HIV-1, which cater to specific patient populations.
What is the highest forecasted price for THTX Theratechnologies Inc.?
The highest price target for THTX is $3.81 from at , which represents a 146.4% increase from the current price of $1.55.
What is the lowest forecasted price for THTX Theratechnologies Inc.?
The lowest price target for THTX is $3.81 from at , which represents a 146.4% increase from the current price of $1.55.
What is the overall THTX consensus from analysts for Theratechnologies Inc.?
The overall analyst consensus for THTX is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.81.
How accurate are THTX stock price projections?
Stock price projections, including those for Theratechnologies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
